STAT-3 Correlates with Lymph Node Metastasis and Cell Survival in Gastric Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2010 Nov 13

PMID 21072904

Citations 52

Authors

Jing-Yu Deng

Dan Sun

Xiang-Yu Liu

Yi Pan

Han Liang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the correlation between gastric cancer growth and signal transducer and activator of transcription-3 (STAT3) expression.

Methods: We assessed the expressions of STAT3, phosphor-STAT3 (pSTAT3), suppressor of cytokine signaling-1 (SOCS-1), survivin and Bcl-2 in gastric cancer patients after gastrectomy by immunohistochemical method. In addition, in situ hybridization was used to further demonstrate the mRNA expression of STAT3 in gastric cancer.

Results: With the univariate analysis, expressions of STAT3, pSTAT3, SOCS-1, survivin and Bcl-2, the size of primary tumor and the lymph node metastasis were found to be associated with the overall survival (OS) of gastric cancer patients. However, only pSTAT3 expression and the lymph node metastasis were identified as the independent factors of OS of gastric cancer with multivariate analysis. STAT3 expression was correlated with the lymph node metastasis. There were positive correlations between expressions of STAT3, survivin, Bcl-2 and pSTAT3 in gastric cancer, whereas there was negative correlation between STAT3 expression and SOCS-1 expression in gastric cancer.

Conclusion: STAT3 can transform into pSTAT3 to promote the survival and inhibit the apoptosis of gastric cancer cells. SOCS-1 might be the valid molecular antagonist to inhibit the STAT3 expression in gastric cancer.

Citing Articles

Clinicopathological significance of JAK2, STAT3, and STAT4 expression in patients with gastric solid-type poorly differentiated adenocarcinoma: a retrospective study.

Umekita S, Kiyozawa D, Honma H, Kohashi K, Taniguchi Y, Kawatoko S Gastric Cancer. 2025; .

PMID: 39961990 DOI: 10.1007/s10120-025-01589-8.

Prognostic Value and Therapeutic Significance of CCL Chemokines in Gastric Cancer.

Tian Y, Xie Y, Yi G, Wu F, Dang X, Bai F Curr Med Chem. 2024; 31(42):7043-7058.

PMID: 39129286 DOI: 10.2174/0109298673315146240731100101.

Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines.

Huber A, Allam A, Dijkstra C, Thiem S, Huynh J, Poh A Cell Rep. 2024; 43(8):114616.

PMID: 39128004 PMC: 11372443. DOI: 10.1016/j.celrep.2024.114616.

The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.

Zhao R, Hu Z, Zhang X, Huang S, Yu G, Wu Z Cell Commun Signal. 2024; 22(1):68.

PMID: 38273295 PMC: 10809652. DOI: 10.1186/s12964-023-01421-9.

Study on the Mechanism of Action of STAT3 in the Drug Resistance of Gastric Cancer Cells.

Di J, Jiang B, Shang H, Yang X, Zhang C, Shi X Contrast Media Mol Imaging. 2022; 2022:1426343.

PMID: 35992548 PMC: 9356858. DOI: 10.1155/2022/1426343.

References

Jackson C, Giraud A . STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol. 2009; 24(4):505-7. DOI: 10.1111/j.1440-1746.2009.05822.x. View

Scholz A, Heinze S, Detjen K, Peters M, Welzel M, Hauff P . Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 2003; 125(3):891-905. DOI: 10.1016/s0016-5085(03)01064-3. View

Vidal O, Soriano-Izquierdo A, Pera M, Elizalde J, Palacin A, Castells A . Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg. 2007; 12(6):1005-14. DOI: 10.1007/s11605-007-0336-3. View

Starr R, Willson T, Viney E, Murray L, Rayner J, Jenkins B . A family of cytokine-inducible inhibitors of signalling. Nature. 1997; 387(6636):917-21. DOI: 10.1038/43206. View

Chan A, Luk J, Hui W, Lam S . Molecular biology of gastric carcinoma: from laboratory to bedside. J Gastroenterol Hepatol. 2000; 14(12):1150-60. DOI: 10.1046/j.1440-1746.1999.02000.x. View

Choi J, Ahn M, Park C, Han H, Kwon S, Lee Y . Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. APMIS. 2006; 114(9):619-25. DOI: 10.1111/j.1600-0463.2006.apm_401.x. View

Siewert J, Bottcher K, Stein H, Roder J . Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998; 228(4):449-61. PMC: 1191515. DOI: 10.1097/00000658-199810000-00002. View

Kim D, Cha S, Ahn D, Kang H, Kwon C, Ko K . STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol. 2009; 24(4):646-51. DOI: 10.1111/j.1440-1746.2008.05671.x. View

Xie K, Huang S . Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis. 2003; 20(1):31-43. DOI: 10.1023/a:1022590402748. View

10.

Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T . STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004; 23(28):4921-9. DOI: 10.1038/sj.onc.1207606. View

11.

Bowman T, Garcia R, Turkson J, Jove R . STATs in oncogenesis. Oncogene. 2000; 19(21):2474-88. DOI: 10.1038/sj.onc.1203527. View

12.

Rottapel R, Ilangumaran S, Neale C, La Rose J, Barber D, Dubreuil P . The tumor suppressor activity of SOCS-1. Oncogene. 2002; 21(28):4351-62. DOI: 10.1038/sj.onc.1205537. View

13.

Pisani P, Parkin D, Bray F, Ferlay J . Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83(1):18-29. DOI: 10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m. View

14.

Aoki Y, Feldman G, Tosato G . Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2002; 101(4):1535-42. DOI: 10.1182/blood-2002-07-2130. View

15.

Gong W, Wang L, Yao J, Ajani J, Wei D, Aldape K . Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005; 11(4):1386-93. DOI: 10.1158/1078-0432.CCR-04-0487. View

16.

Lee J, Kang W, Park J, Park S, Park Y, Lim H . Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS. 2009; 117(8):598-606. DOI: 10.1111/j.1600-0463.2009.02512.x. View

17.

Fukushima N, Sato N, Sahin F, Su G, Hruban R, Goggins M . Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer. 2003; 89(2):338-43. PMC: 2394272. DOI: 10.1038/sj.bjc.6601039. View

18.

Galm O, Yoshikawa H, Esteller M, Osieka R, Herman J . SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2002; 101(7):2784-8. DOI: 10.1182/blood-2002-06-1735. View

19.

Nicholson S, Willson T, Farley A, Starr R, Zhang J, Baca M . Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999; 18(2):375-85. PMC: 1171132. DOI: 10.1093/emboj/18.2.375. View

20.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View